Journal Information
Vol. 45. Issue S3.
Controversias de formación en neumología
Pages 22-27 (March 2009)
Share
Share
Download PDF
More article options
Vol. 45. Issue S3.
Controversias de formación en neumología
Pages 22-27 (March 2009)
Full text access
Manejo de la patología pleural
Management of pleural disease
Visits
15681
Francisco Rodríguez-Panaderoa,
Corresponding author
frpanad@ono.com

Autor para correspondencia.
, Myriam Aguilar Pérezb, Manuel Alejandro Muñoz Moyac, María Isabel Asensio Cruza
a Unidad Médico-Quirúrgica de Enfermedades Respiratorias, Hospital Universitario Virgen del Rocío, Sevilla, España
b Servicio de Neumología, Hospital Universitario 12 de Octubre, Madrid, España
c Unidad de Neumología, Consorcio hospitalario provincial de Castellón, Castellón, España
This item has received
Article information
Abstract
Bibliography
Download PDF
Statistics
Resumen

Teniendo en cuenta las ponencias presentadas en el I Foro Nacional de Neumólogos en Formación, nos centramos aquí en los derrames pleurales de origen infeccioso y sobre el estudio de posibles marcadores de malignización en sujetos con historia de exposición a asbesto. Se analiza el rendimiento de las distintas técnicas para el diagnóstico del derrame tuberculoso, haciendo hincapié en el estudio del esputo y de las muestras pleurales (líquido y tejido) para Mycobacteriumtuberculosis, y en el rendimiento de la adenosindesaminasa (ADA) (en ausencia de empiema, ADA > 70 U/l es diagnóstico de pleuritis tuberculosa, y niveles inferiores a 40 U/l la excluyen prácticamente) e interferón gamma en el líquido pleural (punto de corte: 3,7 UI/ml). El manejo de los derrames pleurales paraneumónicos se estratifica en cuatro categorías, atendiendo a las características anatomo-morfológicas (tamaño y eventual presencia de loculación), bacteriológicas (positividad o no del cultivo del líquido pleural) y bioquímicas (pH/glucosa) del derrame. Finalmente, se describen algunos marcadores desarrollados recientemente para el estudio y seguimiento de personas expuestas a asbesto, con especial hincapié en la determinación de niveles de mesotelina en suero, que parece muy prometedora como marcador del desarrollo de mesotelioma en estos casos. Niveles de SMRP (proteínas solubles relacionadas con la mesotelina) superiores a 0,55 nmol/l mostraron un 72% de sensibilidad y especificidad para el diagnóstico de mesotelioma maligno de estirpe epitelial en un estudio multicéntrico que actualmente se está llevando a cabo en nuestro país.

Palabras clave:
Adenosindesaminasa
Derrame paraneumónico
Derrame pleural
Empiema
Interferón gamma
Mesotelina
Mesotelioma
Tuberculosis pleural
Abstract

In view of the presentations in the First National Forum of Trainee Pneumologists, the present article focusses on infectious pleural effusions and on the study of possible markers of malignant disease in asbestos-exposed individuals. The yield of the distinct techniques for the diagnosis of tuberculous pleural effusion is assessed, with emphasis on analysis of sputum and pleural samples (fluid and tissue) for Mycobacteriumtuberculosis. The utility of adenosine deaminase (ADA) (in the absence of empyema, ADA > 70 U/l is diagnostic of tuberculous pleurisy, while values of less than 40 U/l exclude this diagnosis) and interferon gamma in pleural fluid (cut off: 3.7 Ul/ml) is also discussed. The management of complicated parapneumonic pleural effusions is stratified in four categories, depending on the anatomical and morphological (size and eventual presence of loculations), bacteriological (positivity or negativity of pleural fluid culture) and biochemical (pH/glucose) characteristics of the effusion. Finally, recently developed markers for the evaluation and follow-up of asbestos-exposed individuals are described, with special emphasis on serum determination of mesothelin levels, which seem highly promising as a marker of the development of mesothelioma in these cases. A multicenter study currently being performed in Spain found that soluble mesothelin-related protein (SMRP) levels higher than 0.55 nmol/L showed a sensitivity and specificity of 72% for the diagnosis of epithelial malignant mesothelioma.

Keywords:
Adenosine deaminase
Parapneumonic effusion
Pleural effusion
Empyema
Interferon gamma
Mesothelin
Mesothelioma
Pleural tuberculosis
Full text is only aviable in PDF
Bibliografía
[1.]
V. Villena Garrido, J. Ferrer Sancho, L. Hernández Blasco, A. De Pablo Gafas, E. Pérez Rodríguez, F. Rodríguez Panadero, et al.
Diagnóstico y tratamiento del derrame pleural.
Arch Bronconeumol, 42 (2006), pp. 349-372
[2.]
M.E. Froudarakis.
Diagnostic work-up of pleural effusions.
Respiration, 75 (2008), pp. 4-13
[3.]
C.W. Davies, F.V. Gleeson, R.J. Davies.
BTS guidelines for the management of pleural infection.
Thorax, 58 (2003), pp. ii18-ii28
[4.]
M.B. Conde, A.C. Loivos, V.M. Rezenda, S.L. Soares, F.C. Mello, A.L. Reingold, et al.
Yield of sputum induction in diagnosis of pleural tuberculosis.
Am J Respir Crit Care Med, 167 (2003), pp. 723-725
[5.]
L. Valdes, S. Alvarez, E. San Jose, P. Penela, J.M. Valle, J.M. Garcia-Pazos, et al.
Tuberculous pleurisy: a study of 254 patients.
Arch Intern Med, 158 (1998), pp. 2017-2021
[6.]
R. Diel, R. Loddenkemper, K. Meywald-Walter, R. Gottschalk, A. Nienhaus.
Comparative Performance of Tuberculin skin test, QuantiFERON_TB_GOLD in tube assay, and T-Spot.TB Test in contact investigations for tuberculosis.
Chest, 135 (2009), pp. 1010-1018
[7.]
M. Pai, A. Zwerling, D. Menzies.
Systematic review: T-cellbased assays for the diagnosis of latent tuberculosis infection; an update.
Ann Intern Med, 149 (2008), pp. 177-184
[8.]
G. Maartens, E. Bateman.
Tuberculous pleural effusions: Increased culture yield with bedside inoculation of pleural fluid and poor diagnostic value of adenosine deaminase.
Thorax, 46 (1991), pp. 96-99
[9.]
J.P.J. Ungerer, H.M. Oosthuizen, J.H. Retief, S.H. Bissbort.
Significance of adenosine deaminase activity and its isoenzymes in tuberculous effusions.
Chest, 106 (1994), pp. 33-37
[10.]
C. Gakis.
ADA1 and ADA2: diagnostic and biological role.
Eur Respir J, 9 (1996), pp. 632-633
[11.]
V. Villena, A. Lopez-Encuentra, F. Pozo, J. Echave-Sustaeta, B. Ortuño-de-Solo, J. Estenoz-Alfaro, et al.
Interferon gamma levels in pleural fluid for the diagnosis of tuberculosis.
Am J Med, 115 (2003), pp. 365-370
[12.]
J.M. Querol, J. Minguez, E. Garcia-Sanchez, M.A. Farga, C. Gimeno, J. Garcia de Lomas.
Rapid diagnosis of pleural tuberculosis by polymerase chain reaction.
Am J Respir Crit Care Med, 152 (1995), pp. 1977-1981
[13.]
V. Villena, M.J. Rebollo, J.M. Aguado, A. Galan, A. Lopez Encuentra, E. Palenque.
Polymerase chain reaction for the diagnosis of pleural tuberculosis in immunocompromised and immunocompetent patients.
Clin Infect Dis, 26 (1998), pp. 212-221
[14.]
D.M. Lima, J.K. Colares, B.A. da Fonseca.
Combined use of the polymerase chain reaction and detection of adenosine deaminase activity on pleural fluid improves the rate of diagnosis of pleural tuberculosis.
Chest, 124 (2003), pp. 909-914
[15.]
J. Fontan Bueso, H. Verea Hernando, J.P. Garcia-Buela, L. Dominguez Juncal, M.T. Martin Egaña, M.C. Montero Martinez.
Diagnostic value of simultaneous determination of pleural adenosine deaminase and pleural lysozyme/serum lysozyme ratio in pleural effusion.
Chest, 93 (1988), pp. 303-307
[16.]
A.H. Diacon, B.W. Van de Wal, C. Wyser, J.P. Smedema, J. Bezuidenhout, C.T. Bolliger, et al.
Diagnostic tools in tuberculous pleurisy: A direct comparative study.
Eur Respir J, 22 (2003), pp. 589-591
[17.]
W.H. Roper, J.J. Waring.
Primary serofibrinous pleural effusion in military personnel.
Am Rev Tuberc, 71 (1955), pp. 616-635
[18.]
C.H. Lee, W.J. Wang, R.S. Lan, Y.H. Tsai, Y.C. Chiang.
Corticosteroids in the treatment of tuberculous pleurisy: a double-blind, placebo-controlled, randomized study.
Chest, 94 (1988), pp. 1256-1259
[19.]
P.T. Matchaba, J. Volmink.
Steroids for treating tuberculous pleurisy.
Cochrane Database System Review, (2000),
[20.]
C.S. Barbas, A. Cukier, C.R. de Varvalho, J.V. Barbas Filho, R.W. Light.
The relationship between pleural fluid findings and the development of pleural thickening in patients with pleural tuberculosis.
Chest, 100 (1991), pp. 1264-1267
[21.]
T.H. Tsai, P.C. Yang.
Ultrasound in the diagnosis and management of pleural disease.
Curr Opin Pulm Med, 9 (2003), pp. 282-290
[22.]
J.E. Heffner, L.K. Brown, C. Barbieri, J.M. DeLeo.
Pleural fluid chemical analysis in parapneumonic effusions.
Am J Respir Crit Care Med, 151 (1995), pp. 1700-1708
[23.]
G.L. Colice, A. Curtis, J. Deslauriers, J. Heffner, R. Light, B. Littenberg, et al.
Medical and surgical treatment of parapneumonic effusions: an evidence-based guideline.
Chest, 118 (2000), pp. 1158-1171
[24.]
H.K.R. Storm, M. Krasnik, K. Bang, N. Frimodt-Moller.
Treatment of pleural empyema secondary to pneumonia: thoracocentesis regimen versus tube drainage.
Thorax, 47 (1992), pp. 821-824
[25.]
S.A. Sahn, R.W. Light.
The sun should never set on a parapneumonic effusion.
Chest, 95 (1989), pp. 945-947
[26.]
R. Cameron, H.R. Davies.
Tratamiento fibrinolítico intrapleural versus tratamiento conservador para los derrames paraneumónicos y el empiema (Revisión Cochrane traducida).
La Biblioteca Cochrane Plus, Update Software Ltd, (2005),
[27.]
Y. Tokuda, D. Matsushima, G.H. Stein, S. Miyagi.
Intrapleural Fibrinolytic Agents for empyema and complicated parapneumonic effusions.
Chest, 129 (2006), pp. 783-790
[28.]
J.S. Moulton, R.E. Benkert, K.H. Weisiger, J.A. Chambers.
Treatment of complicated pleural fluid collections with image-guided drainage and intracavitary urokinase.
Chest, 108 (1995), pp. 1252-1259
[29.]
G.F. Tassi, R.J.O. Davies, M. Noppen.
Advanced techniques in medical thoracoscopy.
Eur Respir J, 28 (2006), pp. 1051-1059
[30.]
R.J. Thurer.
Decortication in thoracic empyema: indications and surgical technique.
Chest Surg Clin N. Am, 6 (1996), pp. 461-490
[31.]
J. Deslauriers, L.F. Jacques, J. Gregoire.
Role of Eloesser flapand thoracoplasty in the third millennium.
Chest Surg Clin N Am, 12 (2002), pp. 605-623
[32.]
B.T. Mossman, D.W. Kamp, S.A. Weitzman.
Mechanisms of carcinogenesis and clinical features of asbestos-associated cancers.
Cancer Invest, 14 (1996), pp. 466-480
[33.]
B.W. Robinson, R.A. Lake.
Advances in malignant mesothelioma.
N Engl J Med, 353 (2005), pp. 1591-1603
[34.]
H.I. Pass, D. Lott, F. Leonardo, M. Harbut, Z. Liu, N. Tang, et al.
Asbestos exposure, pleural mesothelioma, and serum osteopontin levels.
N Engl J Med, 353 (2005), pp. 1564-1573
[35.]
B.D. Grigoriu, A. Scherpereel, P. Devos, B. Chahine, M. Letourneux, P. Lebailly, et al.
Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment.
Clin Cancer Res, 13 (2007), pp. 2928-2935
[36.]
J. Creaney, D. Yeoman, Y. Demelker, A. Segal, A.W. Musk, S.J. Skates, et al.
Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma.
J Thorac Oncol, 3 (2008), pp. 851-857
[37.]
N.G. Ordónez.
Application of mesothelin immunostaining in tumor diagnosis.
Am J Surg Pathol, 27 (2003), pp. 1418-1428
[38.]
B.W.S. Robinson, J. Creaney, R. Lake, A. Nowak, A.W. Musk, N. de Klerk, et al.
Mesothelin-family proteins and diagnosis of mesothelioma.
Lancet, 362 (2003), pp. 1612-1616
[39.]
A. Scherpereel, B. Grigoriu, M. Conti, T. Gey, M. Gregoire, M.C. Copin, et al.
Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma.
Am J Respir Crit Care Med, 173 (2006), pp. 1155-1160
[40.]
J.A. Rodríguez Portal, E. Rodríguez Becerra, D. Rodríguez Rodríguez, I. Alfageme Michavila, A. Quero Martínez, C. Diego Roza, et al.
Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: Relation with past asbestos exposure.
Cancer Epidemiol Biomarkers Prev, 18 (2009), pp. 646-650
[41.]
E.K. Park, A. Sandrini, D.H. Yates, J. Creaney, B.W. Robinson, P.S. Thomas, et al.
Soluble mesothelin-related protein in an asbestos-exposed population: the dust diseases board cohort study.
Am J Respir Crit Care Med, 178 (2008), pp. 832-837
[42.]
B.D. Grigoriu, B. Chahine, F. Zerimech, M. Grégoire, M. Balduyck, M.C. Copin, et al.
Serum mesothelin has a higher diagnostic utility than hyaluronic acid in malignant mesothelioma.
Clin Biochem, 42 (2009), pp. 1046-1050
Copyright © 2009. Sociedad Española de Neumología y Cirugía Torácica
Archivos de Bronconeumología
Article options
Tools

Are you a health professional able to prescribe or dispense drugs?